Persistent Corneal Epithelial Defect (PCED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Persistent corneal epithelial defects (PEDs or PCEDs) arise from the inability to rapidly regenerate and close the corneal surface within 10-14 days following injury, despite standard supportive therapy. Disruptions in the corneal epithelium and stroma's protective layers can lead to severe consequences, including infection, stromal ulceration, perforation, scarring, and significant vision impairment. The multilayered corneal epithelium, held together by tight junctions, is a crucial barrier against infectious agents while maintaining optical smoothness through constant cell regeneration in the basal layer. Various factors contribute to the development of PED, including dry eyes, limbal stem cell deficiency, diabetes mellitus, and neurotrophic issues. Conventional treatments involve frequent application of artificial tears, protective eyewear, and punctal occlusion. However, artificial tears lack essential components like epidermal growth factor (EGF), vitamin A, and transforming growth factor β (TGFβ), crucial for corneal health. Surgical interventions such as debridement and tarsorrhaphy are often necessary for cases unresponsive to medical management. PEDs are categorized into three stages: stage 1 exhibits mild epithelial defects like punctate keratopathy, stage 2 involves persistent epithelial defects, and ulcers characterize stage 3.

·       The annual incidence of persistent corneal epithelial defect (PCED) ranges from 25 to 38 cases per 100,000 people in the USA.

 

Thelansis’s “Persistent Corneal Epithelial Defect (PCED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Persistent Corneal Epithelial Defect (PCED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Persistent Corneal Epithelial Defect (PCED) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Persistent Corneal Epithelial Defect (PCED) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Persistent Corneal Epithelial Defect (PCED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Persistent Corneal Epithelial Defect (PCED), Persistent Corneal Epithelial Defect (PCED) market outlook, Persistent Corneal Epithelial Defect (PCED) competitive landscape, Persistent Corneal Epithelial Defect (PCED) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)